April 2, 2025 was 'Liberation Day.' Trump signed sweeping tariffs — a 10% baseline on all imports, reciprocal rates up to 54% on Chinese goods, and a promise that American factories would roar back. One year later, the anniversary present was another executive order: 100% tariffs on branded pharmaceutical imports. The first round got struck down by the Supreme Court. The second round launched the same week it was supposed to be celebrating results from the first.
Consensus says tariffs are working. Revenue is up. China is hurting. Manufacturing is coming back. The administration says it collected $151 billion in tariff revenue in the first five months of fiscal 2026 — nearly four times the previous year. That's the number they lead with. It's also the number that hides the body.
Manufacturing employment fell by 89,000 jobs from April 2025 to February 2026. Not gained. Fell. No significant manufacturing boom materialized anywhere in the data. Foreign direct investment dropped below historical averages — companies didn't rush to build U.S. plants, they rerouted supply chains through Vietnam and Mexico. The Peterson Institute estimated tariffs cost average American households roughly $1,700 a year in higher prices. And here's the part nobody talks about at the podium: half the $151 billion collected — about $166 billion total across the year — has to be refunded because the Supreme Court ruled the original Liberation Day tariffs exceeded presidential authority in February 2026.
So the government collected money it has to give back, lost the manufacturing jobs it said tariffs would create, and watched companies move production to third countries instead of U.S. soil. Inflation stayed elevated at 2.4% in February, partly driven by tariff pass-through. That's the one-year report card graded on tariff policy's own stated goals.
The new pharmaceutical tariffs announced April 2 add a fresh layer. Branded patented drugs from companies without a pricing deal or U.S. production commitment face 100% tariffs. Large firms get 120 days to comply. Smaller producers get 180 days. Generics are exempt for at least a year — that covers over 90% of medicines Americans take. The EU, Japan, South Korea, and Switzerland negotiated separate caps at 15%. The UK got a zero-tariff deal. Seventeen drugmakers already signed pricing agreements with the administration, thirteen finalized.
Sounds like leverage. The U.S. Chamber of Commerce says it's a healthcare cost increase for families. Onshoring drug manufacturing typically raises costs, not lowers them. GLP-1 drugs alone — Ozempic, Wegovy — carry list prices above $1,000 a month and are manufactured almost entirely overseas. Moving that production to the U.S. in 120 days isn't a deadline. It's a fantasy. The realistic path is pricing deals, which means the tariffs are a threat to force negotiation, not an actual trade policy. That's a familiar pattern from the first Liberation Day: announce extreme tariffs, negotiate exceptions, claim victory while the macro data tells a different story.
The Supreme Court replaced the original tariff package with a temporary scheme expiring July 2026. That means the legal authority for even the reduced tariffs is on a timer. If Congress doesn't codify them, the entire structure resets in three months. Markets aren't pricing that expiration. They should be.
What kills this thesis: manufacturing employment reverses and adds 100,000+ jobs by July 2026, directly attributable to reshoring driven by tariff incentives. Or the Supreme Court's temporary tariff scheme gets extended or codified by Congress before expiration. Or pharmaceutical companies announce credible U.S. manufacturing commitments for at least five major branded drugs within the 120-day compliance window. Or inflation drops below 2.0% despite tariffs staying in place, proving no consumer cost pass-through. Those would change the scorecard. The current data doesn't support any of them.
One year of Liberation Day tariffs produced $151 billion in revenue the government has to refund, 89,000 fewer factory jobs, higher consumer prices, and a Supreme Court rebuke. The new pharma tariffs are a negotiation tool wearing a trade policy costume. Watch the July expiration. That's the real deadline.